{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-110829","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.858662+00:00","generated_at":"2026-05-16T20:08:50.858449+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Traws Pharma reports Q3 net loss $4.0M; Phase 2 ratutrelvir data expected YE 2025","bullets":["Net loss of $4.0M ($0.34 diluted EPS) vs $8.5M ($1.49) in Q3 2024; R&D and G&A expenses down significantly.","Cash and equivalents $6.4M at Sept 30, 2025, down from $21.3M at Dec 31, 2024; runway into Q1 2026.","Acquired key patent from Viriom for $2.6M; intangible assets of $2.6M recorded.","Ratutrelvir Phase 2 studies dosed; topline data from both studies expected by year-end 2025.","Iain Dukes permanently appointed CEO, Charles Parker CFO confirmed Oct 6; John Leaman added to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-110829","json":"https://secwatch.observer/filing/0001104659-25-110829.json","markdown":"https://secwatch.observer/filing/0001104659-25-110829.md","text":"https://secwatch.observer/filing/0001104659-25-110829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/0001104659-25-110829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925110829/tm2531045d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:08:50.858449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}